Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lemzoparlimab - I-MAb Biopharma

Next Previous
Drug Profile

Lemzoparlimab - I-MAb Biopharma

Alternative Names: ABBV-IMAB-TJC4; Anti-CD47 antibody - I-Mab; TJ-011133; TJ-1133; TJC-4

Latest Information Update: 19 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator I-MAB Biopharma
  • Developer AbbVie; I-MAB Biopharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelodysplastic syndromes
  • Discontinued Acute myeloid leukaemia; Gastric cancer; Head and neck cancer; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 23 Apr 2025 I-MAB Biopharma terminates Phase-III clinical trials in Myelodysplastic syndromes (Combination therapy, First-line therapy) in China due to company Development strategy adjustment (IV) (NCT05709093)
  • 05 Jul 2024 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, First-line therapy) in Spain, United Kingdom, Japan, Italy, Germany, Australia, Israel, USA (IV)
  • 05 Jul 2024 Discontinued - Phase-I for Multiple myeloma (Combination therapy, Second-line therapy or greater) in United Kingdom, Spain, Japan, Germany, France, Australia, Israel, USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top